We serve Chemical Name:4-Cyanobenzohydrazide CAS:43038-36-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Cyanobenzohydrazide
CAS.NO:43038-36-4
Synonyms:Benzoic acid, 4-cyano-, hydrazide;4-cyano-benzhydrazide;4-Cyanobenzohydrazide;4-cyanobenzoic hydrazide;4-cyano-benzoic acid hydrazide;4-cyanobenzoylhydrazine;4-Cyan-benzoesaeure-hydrazid;4-benzenecarbonitrile;4CNPhCON2
Molecular Formula:C8H7N3O
Molecular Weight:161.161
HS Code:2928000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.3±0.1 g/cm3
Index of Refraction:1.610
PSA:78.91000
Exact Mass:161.058914
LogP:-0.10
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzoic acid, 4-cyano-, hydrazide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4CNPhCON2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid, 4-cyano-, hydrazide Use and application,4-Cyanobenzohydrazide technical grade,usp/ep/jp grade.
Related News: But Sanofi’s rival CD38 antibody Sarclisa may soon be able to challenge Darzalex in the same front-line, transplant-ineligible population with the help of a more powerful backbone. 4-Cyanobenzohydrazide manufacturer In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 4-Cyanobenzohydrazide supplier Lilly has denied retaliating against any employees, and no lawsuit has been filed on behalf of Mula. 4-Cyanobenzohydrazide vendor With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near 4-Cyanobenzohydrazide factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.
